Canada markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
8.19+0.42 (+5.41%)
At close: 4:00PM EDT
8.16 -0.03 (-0.37%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close7.77
Open7.85
Bid8.19 x 800
Ask8.16 x 900
Day's Range7.80 - 8.27
52 Week Range2.81 - 9.50
Volume725,936
Avg. Volume2,226,171
Market Cap125.845M
Beta (5Y Monthly)1.54
PE Ratio (TTM)8.34
EPS (TTM)0.98
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    October is Breast Cancer Awareness Month – BriaCell is Advancing the Fight with its Immunotherapy

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, acknowledges that October is Breast Cancer Awareness Month, an annual campaign to increase awareness of the disease. Significant progress has been made in breast cancer support, prevention, detection, diagnosis, trea

  • GlobeNewswire

    BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com

    BriaCell Therapeutics CEO Interview BriaCell Therapeutics CEO Emphasizes Recent Key Developments in Audio Interview with SmallCapVoice.com AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss three key achievements that support the Company’s continued growth. BriaCell is a clinical-stage biotechnology company specializ

  • GlobeNewswire

    BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the “TSXV”) has accepted the Company’s Notice of Intention to implement a normal course issuer bid (the “Buyback”). Pursuant to the Buyback, the Company may, during t